Redirector

December 2013 - Volume 22 - Issue 4

  • Mark H. Stoler, MD
  • 1052-9551
  • 1533-4066
  • 4 issues / year
  • Biochemistry & Molecular Biology 193/291
    Biotechnology & Applied Microbiology 115/165
    Pathology 49/76
  • 1.474
 

Dear Diagnostic Molecular Pathology reader,

This letter is to notify you that Lippincott Williams & Wilkins will be merging the publication of Diagnostic Molecular Pathology with Applied Immunohistochemistry & Molecular Morphology (AIMM) effective with the January 2014 issue.

AIMM will now increase its publication to 10 issues per year and broaden its scope and content to provide complete coverage of the diagnostic, prognostic and predictive applications of immunohistochemistry (IHC) and molecular pathology, with an emphasis on applications of diagnostic import. The focus is on the understanding of the biology of tumors and other lesions, and provide up to date information of diagnostic and scientific relevance to practicing and research pathologists.

Please note that the DMP archive will be available on the AIMM website, appliedimmunohist.com. We want to thank you for being dedicated readers of Diagnostic Molecular Pathology, and encourage you to subscribe to the new journal, Applied Immunohistochemistry & Molecular Morphology, now including Diagnostic Molecular Pathology.

For authors who wish to submit their manuscript, please visit the AIMM Editorial Manager site: www.editorialmanager.com/AIMM.

-Tom Pacific

Associate Publisher, WKH

Current Issue Highlights


A Comparison of Methods for EGFR Mutation Testing in Non–Small Cell Lung Cancer

Young, Elizabeth C.; Owens, Martina M.; Adebiyi, Idowu; More

Diagnostic Molecular Pathology . 22(4):190-195, December 2013.

Quick Poll
What is your preferred method for assessing patient lung adenocarcinomas for EGFR inhibitor therapy?
What is your preferred method for assessing patient lung adenocarcinomas for EGFR inhibitor therapy?
What is your preferred method for assessing patient lung adenocarcinomas for EGFR inhibitor therapy?
What is your preferred method for assessing patient lung adenocarcinomas for EGFR inhibitor therapy?
What is your preferred method for assessing patient lung adenocarcinomas for EGFR inhibitor therapy?
 Submit